Hon ANDREW LITTLE (Minister of Health): I'll try to take the member's questions seriatim, and if I've forgotten anything, the member will have to remind me in a later call and I may need more than one call to do this. In relation to Pharmac and the recent issue about decision making, particularly in relation to paediatric oncology, I make this point. Pharmac had commenced a review on that issue in 2019. It had seen, and had had drawn to its attention, that even though its decision making and the number of patients it is making decisions about is very small when compared to the whole range of things Pharmac has to deal with, and the budget is comparatively small compared to the now over a billion-dollar budget a year that Pharmac deals with—it nevertheless considered there was an inconsistency in the way it was making decisions about those medications compared to everything else. It didn't regard it as particularly urgent because of the numbers, but it nevertheless commenced the review; COVID interrupted, and it suspended the review. It then resumed the review once it got notification of an allegation of discrimination that was made to the Human Rights Commission, and the Human Rights Commission commenced an investigation.